Lucira Health (OTCMKTS:LHDXQ) and Oruka Therapeutics (NASDAQ:ORKA) Head-To-Head Contrast

Oruka Therapeutics (NASDAQ:ORKA) and Lucira Health (OTCMKTS:LHDXQ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Oruka Therapeutics and Lucira Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	4	2	3.33
Lucira Health	0	0	0	0	N/A

Oruka Therapeutics currently has a consensus target price of $41.25, indicating a potential upside of 61.96%. Given Oruka Therapeutics’ higher possible upside, research analysts plainly believe Oruka Therapeutics is more favorable than Lucira Health.

Profitability

This table compares Oruka Therapeutics and Lucira Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Lucira Health	N/A	N/A	N/A

Insider and Institutional Ownership

0.1% of Lucira Health shares are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Oruka Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Lucira Health has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500.

Earnings and Valuation

This table compares Oruka Therapeutics and Lucira Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$5.34 million	N/A	N/A
Lucira Health	$93.06 million	0.00	-$64.83 million	($3.58)	0.00

Oruka Therapeutics has higher earnings, but lower revenue than Lucira Health.

Summary

Lucira Health beats Oruka Therapeutics on 6 of the 10 factors compared between the two stocks.

About Oruka Therapeutics

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

About Lucira Health

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.